MedImmune Leverages Spirogen Tech In ADC Collaboration With Tanabe
This article was originally published in Scrip
MedImmune LLC is combining the second-generation pyrollobenzodiazepine (PBD) warheads it picked up in a 2013 buyout of Spirogen Ltd. with Tanabe Research Laboratories USA Inc.'s antibodies in a collaboration to develop mono-specific and bi-specific antibody-drug conjugates (ADCs) against a set of cancer targets.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.